The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date

References

• Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12(10):566–592. doi:10.1038/nrendo.2016.8627339889
   PubMed Web of Science ®Google Scholar
• Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabetic Med. 2013;30(3):289–299. doi:10.1111/j.1464-5491.2012.03746.x22804451
   PubMed Web of Science ®Google Scholar
• Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13:142. doi:10.1186/1475-2840-13-8025338737
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Toulis KA, Hanif W, Saravanan P, et al. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study. Diabetes Metab. 2017;43(3):211–216. doi:10.1016/j.diabet.2017.02.00328325589
   PubMed Web of Science ®Google Scholar
• Taylor KS, Heneghan CJ, Farmer AJ, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–2371. doi:10.2337/dc12-151323435157
   PubMed Web of Science ®Google Scholar
• Mullard A. Oral GLP1 analogue rounds Phase II corner. Nat Rev Drug Discov. 2015;14:227.
   Web of Science ®Google Scholar
• Andersen A, Lund A. Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology. 2018;14(7):390–403.
   Google Scholar
• OZEMPIC® (semaglutide) injection 0.5mg/1mg [prescribing information]; Novo Nordisk; 2017 Available from: https://www.novo-pi.com/ozempic.pdf. Accessed July 27, 2019.
   Google Scholar
• EMA. Summary of the European public assessment report (EPAR) for Ozempic. 2018 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/004174/human_med_002211.jsp&mid=WC0b01ac058001d124. Accessed July 27, 2019.
   Google Scholar
• Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425–1432. doi:10.2337/dc16-197428801473
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–897. doi:10.1111/dom.1317229178519
   PubMed Web of Science ®Google Scholar
• Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20(6):481–501. doi:10.3109/1061186X.2012.69349922632037
   PubMed Web of Science ®Google Scholar
• Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005;19(3):165–177. doi:10.2165/00063030-200519030-0000315984901
   PubMed Web of Science ®Google Scholar
• Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41. doi:10.1016/j.ejps.2017.03.02028323117
   PubMed Web of Science ®Google Scholar
• Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23(14):4011–4018. doi:10.1016/j.bmcl.2013.05.02223743288
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b0072626308095
   PubMed Web of Science ®Google Scholar
• Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504. doi:10.1002/jcph.44325475122
   PubMed Web of Science ®Google Scholar
• Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 2018;57:1529–1538. doi:10.1007/s40262-018-0668-z29915923
   PubMed Web of Science ®Google Scholar
• Madsen K, Knudsen LB, Agersoe H, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126–6132. doi:10.1021/jm070861j17975905
   PubMed Web of Science ®Google Scholar
• Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998–1005. doi:10.1111/dom.1318629205786
   PubMed Web of Science ®Google Scholar
• Marbury TC, Flint A, Jacobsen JB, Derving Karsbol J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381–1390. doi:10.1007/s40262-017-0528-228349386
   PubMed Web of Science ®Google Scholar
• Bloomgarden Z. The kidney and cardiovascular outcome trials. J Diabetes. 2018;10(2):88–89. doi:10.1111/1753-0407.1261629031006
   PubMed Web of Science ®Google Scholar
• Hausner H, Derving Karsbol J, Holst AG, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2017;56(11):1391–1401. doi:10.1007/s40262-017-0532-628349387
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi:10.1016/S2213-8587(17)30013-X28110911
   PubMed Web of Science ®Google Scholar
• Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354. doi:10.1016/S2213-8587(17)30092-X28385659
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. doi:10.2337/dc17-041729246950
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.28344112
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi:10.1016/S2213-8587(18)30024-X29397376
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301. doi:10.1210/jc.2018-0007029688502
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa160714127633186
   PubMed Web of Science ®Google Scholar
• Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443–1467. doi:10.4155/tde.13.10424228993
   PubMedGoogle Scholar
• Ma S, We L, Yang H, Deng S, Anthony M, Jevnikar AM. Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM). Can J Biotech. 2017;1(1):1–10. doi:10.24870/cjb.2017-000107
   Google Scholar
• Buckley STSS, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(suppl 61):1206–P.
   Google Scholar
• Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2(4):289–295. doi:10.1038/nrd106712669028
   PubMed Web of Science ®Google Scholar
• Riley MG, Castelli MC, Paehler EA. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. 2009;28(4):278–293. doi:10.1177/109158180933773719636071
   PubMed Web of Science ®Google Scholar
• Castelli MC, Wong DF, Friedman K, Riley MG. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther. 2011;33(7):934–945. doi:10.1016/j.clinthera.2011.05.08821722960
   PubMed Web of Science ®Google Scholar
• Baekdal TA, Thomsen M, Kupcova V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58:1314–1323. doi:10.1002/jcph.v58.1029693715
   PubMed Web of Science ®Google Scholar
• Granhall C, Sondergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57:1571–1580. doi:10.1007/s40262-018-0649-229623579
   PubMed Web of Science ®Google Scholar
• Baekdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869–877. doi:10.1080/17425255.2018.148896529897249
   PubMed Web of Science ®Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470. doi:10.1001/jama.2017.1475229049653
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes. Diabetes Care. 2019:dc190749. doi:10.2337/dc19-0749
   Web of Science ®Google Scholar
• Montanya E, Rosenstock J, Canani LH, et al. 54-OR: oral semaglutide vs. empagliflozin added on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2. Diabetes. 2019;68(Supplement 1):54–OR. doi:10.2337/db19-54-OR
   Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321:1466. doi:10.1001/jama.2019.294230903796
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019. doi:10.1016/S0140-6736(19)31271-1
   PubMed Web of Science ®Google Scholar
• BUSE JB, BODE BW, CHO YM, et al. 983-P: effect and safety of flexible dose adjustment with oral semaglutide vs. sitagliptin in type 2 diabetes: PIONEER 7. Diabetes. 2019;68(Supplement 1):983–P. doi:10.2337/db19-983-P
   Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. Epub June 11, 2019. doi:10.1056/NEJMoa1901118
   Web of Science ®Google Scholar
• Mosenzon O, Rosenlund S, Eriksson JW, et al. 1004-P: oral semaglutide vs. placebo in patients with type 2 diabetes and moderate renal impairment: PIONEER 5. Diabetes. 2019;68(Supplement 1):1004–P. doi:10.2337/db19-1004-P
   Web of Science ®Google Scholar
• ZINMAN B, ARODA VR, BUSE JB, et al. 985-P: oral semaglutide as add-on to insulin in T2D: PIONEER 8. Diabetes. 2019;68(Supplement 1):985–P. doi:10.2337/db19-985-P
   Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649. doi:10.1016/S0140-6736(18)31773-230122305
   PubMed Web of Science ®Google Scholar
• Lingvay I, Desouza CV, Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41(9):1926–1937. doi:10.2337/dc17-238130026333
   PubMed Web of Science ®Google Scholar
• Korsatko S, Jensen L. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2018;20:2565–2573. doi:10.1111/dom.2018.20.issue-1129893488
   PubMed Web of Science ®Google Scholar
• Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–388. doi:10.1111/dom.1308228786547
   PubMed Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–241. doi:10.2337/dc15-016526358288
   PubMed Web of Science ®Google Scholar
• Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obes Metab. 2018;20(5):1202–1212. doi:10.1111/dom.1321829322610
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461–2498. doi:10.1007/s00125-018-4729-530288571
   PubMed Web of Science ®Google Scholar